ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at The JMP Securities CNS Forum on Wednesday, August 19, 2020, at 11:00 a.m. Eastern Time.

The conference will be held virtually. A live webcast of ACADIA’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through September 19, 2020.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA’s development efforts are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, and an early-stage muscarinic receptor program. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

Contacts:

Media Contact:
ACADIA Pharmaceuticals Inc.
Eric Endicott
(858) 914-7161
[email protected]

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.